Stock Analiz

Assembly Biosciences, Inc. ASMB

Biotechnology: Pharmaceutical Preparations · IPO 2010 · data as of November 13, 2026

$21.12Market cap $432M
Open the interactive analysis →

Assembly Biosciences, Inc. (ASMB) is a healthcare company listed in the US with a market value of about $432M. In fiscal year 2025 it had revenue of $72M and net income of -$6M, a net margin of -8.5%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a P/E of 28.2, 5-year revenue growth of -2% a year, a 5-year average ROIC of -81%.

About Assembly Biosciences

Assembly Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2010. Revenue went from $9M in 2017 to $72M in 2025, growth of about 29.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 178% over three years (dilution for shareholders). It spends 90% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)28.2
Forward P/E—
P/FCF—
P/S6.0
P/B1.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-9.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)153.5%
Revenue growth (5 yrs, per year)-1.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-770.1%
ROIC (5-yr avg.)-81.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$72M$29M$7M$0$6M$79M$16M$15M$9M$0
Net income-$6M-$40M-$61M-$93M-$130M-$62M-$98M-$91M-$43M-$44M
Free cash flow-$41M-$51M$22M-$85M-$96M-$63M-$86M-$65M$995000-$35M
EPS (diluted)$-0.55$-6.69$-13.38$-23.08$-36.00$-21.00$-44.64$-47.76$-28.92$-30.84
Net margin-8.5%-140.9%-854.8%—-2076.3%-78.6%-611.6%-613.0%-474.7%—
ROIC-5.8%-98.5%-117.6%-109.3%-74.2%-25.8%-35.7%-32.6%-38.1%-55.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $51.20, 142% above the current price; targets range from $43.00 to $62.00; the consensus rating is “Strong buy”; expected EPS is $-0.12 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Assembly Biosciences’s P/E ratio?

About 28.2, based on the last twelve months of diluted earnings per share.

Does Assembly Biosciences pay a dividend?

Not currently.

Is Assembly Biosciences a good stock to buy?

We do not give buy or sell advice. Assembly Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.